Idarucizumab for dabigatran reversal: updated results of the RE-VERSE AD study. Presented on 15 November at the American Heart Association (AHA) Scientific Sessions 2016, New Orleans, Louisiana - Pollack, C V, jr.; Reilly, P A; Eikelboom, J